3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
20
Carcinoma, Non-Small-Cell Lung
18
Neoplasms
10
Adenocarcinoma
8
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
6
Esophageal Neoplasms
5
Carcinoma, Renal Cell
5
Breast Neoplasms
5
Colonic Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Melanoma
3
Liver Neoplasms
3
Biliary Tract Neoplasms
3
Ureteral Neoplasms
2
Solid Tumors
2
Sarcoma
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Non-small Cell Lung Cancer Metastatic
2
Malignant Solid Tumor
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Transitional Cell
2
Solid Tumor
1
Solid Cancer
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Gastric Adenocarcinoma
×
Ramucirumab
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts